初诊2型糖尿病采用吡格列酮和二甲双胍治疗效果及对胰岛素抵抗、生活质量改善作用的对比研究

A Comparative Study of the Effect of Pioglitazone and Metformin on Newly Diagnosed Type 2 Diabetes and Its Effect on Insulin Resistance and Quality of Life

目的研究分析初诊2型糖尿病患者采用吡格列酮和二甲双胍的治疗效果以及对胰岛素抵抗、生活质量的改善作用。方法将该院于2018年12月—2019年12月接收的94例初诊2型糖尿病患者分成常规组(二甲双胍)、研究组(吡格列酮),每个小组47例。观察两组血糖水平、糖化血红蛋白、空腹C肽、胰岛素抵抗指数、生活质量。结果研究组与常规组餐后2 h血糖、空腹血糖、糖化血红蛋白在用药前后差异无统计学意义(P>0.05),但研究组用药后空腹C肽、胰岛素抵抗指数水平低于常规组(P<0.05);研究组与常规组用药后生活质量评分高于用药前,但组间差异无统计学意义(P>0.05)。结论二甲双胍与吡格列酮都能够显著降低患者血糖水平,改善其生活质量。但相比而言,吡格列酮对初诊2型糖尿病患者的胰岛素抵抗指数水平改善作用更加突出。

Objective To study and analyze the effects of pioglitazone and metformin on newly diagnosed patients with type 2 diabetes and the effects on insulin resistance and quality of life.Methods The 94 newly diagnosed type 2 diabetes patients received by the hospital from December 2018 to December 2019 were divided into a conventional group(metformin)and a research group(pioglitazone),with 47 cases in each group.Observe the blood glucose level,glycated hemoglobin,fasting C-peptide,insulin resistance index and quality of life in both groups.Results There was no statistically significant difference between the study group and the conventional group after 2 hours of blood glucose,fasting blood glucose,and glycated hemoglobin before and after medication(P>0.05),but the fasting C-peptide and insulin resistance index levels of the study group after medication were lower than the conventional group(P<0.05);the quality of life score of the study group and the conventional group after medication was higher than before,but there was no statistically significant difference between the groups(P>0.05).Conclusion Both metformin and pioglitazone can significantly reduce patients'blood glucose levels and improve their quality of life.However,in comparison,pioglitazone has a more prominent effect on improving the level of insulin resistance in newly diagnosed patients with type 2 diabetes.